pharmaphorum1d
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to ...
Viking Therapeutics closer to bringing its Ozempic competitor to market
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...